San Francisco-based Done Global Inc. is under investigation by U.S. Drug Enforcement Agency over its practices of prescribing controlled substances like Adderall to treat ADHD, according to a report by the Wall Street Journal.
The report, based on documents viewed by the Journal and people familiar with the inquiries, said the DEA has questioned people about its practices.
In an emailed statement, a Done spokesperson said the company has not been contracted by the "Drug Enforcement Agency, Department of Justice, or any other federal agency regarding an investigation."
"Done is committed to providing high-quality psychiatric chronic care management to our members while complying with all applicable laws and regulations," the company spokesperson said.
News of the probe comes just a few months after Cerebral, another mental health startup based in San Francisco, was also questioned by agents of the DEA as part of a federal investigation.
Done, Cerebral and other similar companies rose to prominence during the pandemic when the DEA temporarily waived a rule that required controlled medicines to be prescribed in person. This allowed telehealth companies that specialized in mental health to begin prescribing stronger medicine and oft-abused medicine like Adderall and Xanax.
Critics of the companies and some former employees accused Done and Cerebral of overprescribing medication to drive customer growth.
Done is one of the last holdouts of companies still prescribing Adderall online after Cerebral announced it would no longer prescribe the drug and another competitor Ahead was shut down by its parent company, Truepill.
The Journal said the DEA declined to comment.
